Cachexia, muscle wasting, and frailty in cardiovascular disease

Eur J Heart Fail. 2020 Dec;22(12):2314-2326. doi: 10.1002/ejhf.2011. Epub 2020 Oct 14.

Abstract

The last several years have seen increasing interest in understanding cachexia, muscle wasting, and physical frailty across the broad spectrum of patients with cardiovascular illnesses. This interest originally started in the field of heart failure, but has recently been extended to other areas such as atrial fibrillation, coronary artery disease, peripheral artery disease as well as to patients after cardiac surgery or transcatheter aortic valve implantation. Tissue wasting and frailty are prevalent among many of the affected patients. The ageing process itself and concomitant cardiovascular illness decrease lean mass while fat mass is relatively preserved, making elderly patients particularly prone to develop wasting syndromes and frailty. The aim of this review is to provide an overview of the available knowledge of body wasting and physical frailty in patients with cardiovascular illness, particularly focussing on patients with heart failure in whom most of the available data have been gathered. In addition, mechanisms of wasting and possible therapeutic targets are discussed.

Keywords: Cachexia; Cardiovascular disease; Frailty; Heart failure; Sarcopenia; Wasting.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Cachexia* / epidemiology
  • Cachexia* / physiopathology
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / physiopathology
  • Comorbidity
  • Frailty* / epidemiology
  • Frailty* / physiopathology
  • Humans
  • Inflammation / epidemiology
  • Inflammation / physiopathology
  • Sarcopenia* / epidemiology
  • Sarcopenia* / physiopathology